A multicenter, double-blind, randomised, placebo-controlled, parallel-group trial to investigate the efficacy and safety of SPM 927 (200mg/day and 400mg/day) as adjunctive therapy in subjects with partial seizures with or without secondary generalization

Trial Profile

A multicenter, double-blind, randomised, placebo-controlled, parallel-group trial to investigate the efficacy and safety of SPM 927 (200mg/day and 400mg/day) as adjunctive therapy in subjects with partial seizures with or without secondary generalization

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Epilepsy; Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 01 Mar 2009 Results published in Epilepsia.
    • 08 Dec 2008 Results of a pooled analysis, which included this trial, were presented at the 62nd Annual Meeting of the American Epilepsy Society.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top